Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Proceeds are earmarked for the commercial rollout of the OncoSil device in Australia and the US.
Normalized NPAT surges 108% to $93.3 million, driven by record net flows of $1.4 billion and robust performance fees.
The Australian market is experiencing a mixed performance, with recent fluctuations influenced by global events such as rising oil prices and geopolitical tensions. Despite these challenges, the allure of penny stocks remains strong for investors seeking opportunities in smaller or newer companies. Although the term 'penny stock' might seem outdated, these stocks can offer affordability and growth potential when backed by solid financials.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.